Engineered Nanoparticles for Drug Delivery in Cancer Therapy
The DOI matches its Crossref record; 579 of the 579 references it cites were found in a registry or an index.
Abstract
In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half‐life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real‐time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next‐generation platform for cancer therapy and many other biomedical applications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Vasculature plays an essential role in the growth and metastasis of malignant tumors [103].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
In the citing paper
“Endothelial cells, fibroblasts, and immune cells are the three main cell types which appear in most cancers and are vital components in enhancing the drug resistance of tumors [103, 114-120].”
From Microfluidic modelling of the tumor microenvironment for anti-cancer drug development (2019) · cites this paper as [103]
Citations
Cites
Ordered mesoporous molecular sieves synthesized by a liquid-crystal template mechanism
Kresge, C. T., Leonowicz, M. E., Roth, W. J., Vartuli, J. C., & Beck, J. S. (1992) · Nature · doi:10.1038/359710a0 · Cited by 16,275
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Chemistry and Properties of Nanocrystals of Different Shapes
Burda, C., Chen, X., Narayanan, R., & El-Sayed, M. A. (2005) · Chemical Reviews · doi:10.1021/cr030063a · Cited by 7,230
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Stimuli-responsive nanocarriers for drug delivery
Mura, S., Nicolas, J., & Couvreur, P. (2013) · Nature Materials · doi:10.1038/nmat3776 · Cited by 6,289
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier
Makadia, H. K., & Siegel, S. J. (2011) · Polymers · doi:10.3390/polym3031377 · Cited by 4,816
Research works printed but not linked: 29
- Aruna U., 2013, Inter. J. Inn. Pharm. Res., 4, 318
- Langer R., 1998, Nature, 392, 5
- Petre C. E., 2007, Int. J. Nanomed., 2, 277
- Lao J., 2013, J. Drug Delivery, 456409
- Saif M. W., 2007, JOP, 8, 166
- Matsumura Y., 1986, Cancer Res., 46, 6387
- Xu G., 2001, Clin. Cancer Res., 7, 3314
- 10.1016/j.addr.2012.09.008 · doi:10.1016/j.addr.2012.09.008 · Paper page
- Pundir S., 2013, Int. J. Drug Res. Technol., 3, 12
- 10.1021/jp077468 · doi:10.1021/jp077468
- Mohanraj V. J., 2006, J. Pharm. Res., 5, 561
- Ma Y. D., 2011, Int. J. Nanomed., 6, 2679
- 10.1002/(SICI)1097-4636(199908)46:2<236::AID-JBM13>3.0.CO;2-F · doi:10.1002/(sici)1097-4636(199908)46:2<236::aid-jbm13>3.0.co;2-f
- Krishna R., 2000, Eur. J. Cancer Sci., 11, 265
- Kettiger H., 2013, Int. J. Nanomed., 8, 3255
- Yuan F., 1995, Cancer Res., 55, 3752
- Jain R. K., 1987, Cancer Res., 47, 3039
- 10.1021/nn900002m · DOI · Paper page
- Chidambaram M., 2012, Int. J. Pharm. Sci., 2, 117
- 10.1039/C1CS15237H · DOI · Paper page
- 10.1038/nnano.2007.223 · DOI · Paper page
- Mohanraj V. J., 2006, Trop. J. Pharm. Res., 5, 561
- Hong R. L., 1999, Clin. Cancer Res., 5, 3645
- Shamsipour F., 2009, Avicenna J. Med. Biotechnol., 1, 27
- Park J. W., 2002, Clin. Cancer Res., 8, 1172
- Uppada S. B., 2014, Int. J. Nanomed., 9, 43
- Bangham A. D., 1965, J. Mol. Biol., 13, 227
- Mueller C., 1994, Methods Cell Sci., 16, 183
- 10.1016/j.cbpa.2005.10.005 · DOI
Cited by
Items 401–500 of 1,005
Makvandi, P., Ghomi, M., Ashrafizadeh, M., Tafazoli, A., Agarwal, T., Delfi, M., Akhtari, J., Zare, E. N., Padil, V. V. T., Zarrabi, A., et al. (2020) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2020.116952 · Cited by 81
Hybrid nanostructures: Versatile systems for biomedical applications
Mehta, S., Suresh, A., Nayak, Y., Narayan, R., & Nayak, U. Y. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214482 · Cited by 82
Zhang, H., Zhang, L., Cao, Z., Cheong, S., Boyer, C. A., Wang, Z., Yun, S. L. J., Amal, R., & Gu, Z. (2022) · Small · doi:10.1002/smll.202200299 · Cited by 82
Protein and mRNA Delivery Enabled by Cholesteryl‐Based Biodegradable Lipidoid Nanoparticles
Li, Y., Jarvis, R., Zhu, K., Glass, Z., Ogurlu, R., Gao, P., Li, P., Chen, J., Yu, Y., Yang, Y., et al. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202004994 · Cited by 75
Strategies for transitioning macrocyclic peptides to cell-permeable drug leads
Walport, L. J., Obexer, R., & Suga, H. (2017) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2017.07.007 · Cited by 77
Hussain, M., Raja, N. I., Iqbal, M., & Aslam, S. (2017) · Iranian Journal of Science and Technology Transactions A Science · doi:10.1007/s40995-017-0431-6 · Cited by 86
From biomarkers to therapeutic targets—the promises and perils of long non-coding RNAs in cancer
Gutschner, T., Richtig, G., Haemmerle, M., & Pichler, M. (2017) · Cancer and Metastasis Reviews · doi:10.1007/s10555-017-9718-5 · Cited by 83
Zinc overload mediated by zinc oxide nanoparticles as innovative anti-tumor agent
Wiesmann, N., Kluenker, M., Demuth, P., Brenner, W., Tremel, W., & Brieger, J. (2018) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2018.08.002 · Cited by 75
Nanomedicines for developing cancer nanotherapeutics: from benchtop to bedside and beyond
Iqbal, J., Abbasi, B. A., Ahmad, R., Mahmood, T., Ali, B., Khalil, A. T., Kanwal, S., Shah, S. A., Alam, M. M., Badshah, H., et al. (2018) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-018-9352-3 · Cited by 82
Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases
Guo, H., Feng, C., Zhang, W., Luo, Z., Zhang, H., Zhang, T., Ma, C., Zhan, Y., Li, R. P., Wu, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09852-0 · Cited by 79
Motiei, M., Kashanian, S., & Taherpour, A. A. (2016) · Drug Development and Industrial Pharmacy · doi:10.1080/03639045.2016.1254240 · Cited by 74
“EE ð%Þ 1⁄4 1⁄2ðTotal LTZ Free LTZÞ=Total LTZ 100 (1) LC ð%Þ 1⁄4 1⁄2ðTotal LTZ Free LTZÞ=Nanocarrier Weights 100 (2)”
BackgroundCopper sulfide: An emerging adaptable nanoplatform in cancer theranostics
Poudel, K., Gautam, M., Jin, S. G., Choi, H., Yong, C. S., & Kim, J. O. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.03.043 · Cited by 76
Liu, X., Sun, Y., Xu, S., Gao, X., Kong, F., Xu, K., & Tang, B. (2019) · Theranostics · doi:10.7150/thno.34837 · Cited by 76
“Recently, literatures extensively explored the delivery system with focus on nanomaterials, including Au nanoparticles and polymer nanoparticles such as poly (lactic-co-glycolic acid) (PLGA) with functionalization via various targeting ligands like antibodies, nucleic acids and peptides [6-13].”
BackgroundBai, S., Jia, D., Ma, X., Liang, M., Xue, P., Kang, Y., & Xu, Z. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.011 · Cited by 80
A smart multifunctional drug delivery nanoplatform for targeting cancer cells
Hoop, M., Mushtaq, F., Hurter, C., Chen, X., Nelson, B. J., & Pané, S. (2016) · Nanoscale · doi:10.1039/c6nr02228f · Cited by 78
Chen, W., Hou, Y. X., Tu, Z., Gao, L., & Haag, R. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.10.032 · Cited by 81
Wang, X., Li, Y., Li, Q., Neufeld, C. I., Pouli, D., Sun, S., Yang, L., Deng, P. J., Wang, M., Georgakoudi, I., et al. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.037 · Cited by 77
Li, E., Yang, Y., Hao, G., Yi, X., Zhang, S., Pan, Y., Xing, B., & Gao, M. (2018) · Nanotheranostics · doi:10.7150/ntno.25565 · Cited by 74
Bozuyuk, U., Dogan, N. O., & Kızılel, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b11178 · Cited by 77
DNA Nanostructure‐Based Systems for Intelligent Delivery of Therapeutic Oligonucleotides
Hu, Q., Wang, S., Wang, L., Gu, H., & Fan, C. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701153 · Cited by 72
Lang, C., Mission, E. G., Fuaad, A. A. H. A., & Shaalan, M. (2021) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2021.126063 · Cited by 80
Xing, Y., Li, J., Wang, L., Zhu, Z., Yan, J., Liu, Y., & Liu, Q. (2025) · Advanced Materials · doi:10.1002/adma.202417942 · Cited by 80
pH‐Responsive Pharmacological Chaperones for Rescuing Mutant Glycosidases
Mena‐Barragán, T., Narita, A., Matias, D., Tiscórnia, G., Nanba, E., Ohno, K., Suzuki, Y., Higaki, K., Fernández, J. M. G., & Mellet, C. O. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201505147 · Cited by 74
Can dual-ligand targeting enhance cellular uptake of nanoparticles?
Xia, Q., Ding, H., & Ma, Y. (2017) · Nanoscale · doi:10.1039/c7nr01020f · Cited by 73
Augmented glioma-targeted theranostics using multifunctional polymer-coated carbon nanodots
Wang, S., Li, C., Qian, M., Jiang, H., Shi, W., Chen, J., Lächelt, U., Wagner, E., Lu, W., Wang, Y., et al. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.05.040 · Cited by 78
Bai, S., Ma, X., Shi, X., Shao, J., Zhang, T., Wang, Y., Cheng, Y., Xue, P., Kang, Y., & Xu, Z. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13214 · Cited by 75
Lin, F., Wen, D., Wang, X., & Mahato, R. I. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.036 · Cited by 73
Role of particle shape on efficient and organ-based drug delivery
Nejati, S., Vadeghani, E. M., Khorshidi, S., & Karkhaneh, A. (2019) · European Polymer Journal · doi:10.1016/j.eurpolymj.2019.109353 · Cited by 75
Cao, W., Liu, B., Xia, F., Duan, M., Hong, Y., Niu, J., Wang, L., Liu, Y., Li, C., & Cui, D. (2019) · Nanoscale · doi:10.1039/c9nr07947e · Cited by 73
Florensa, M., Llenas, M., Medina-Gutiérrez, E., Sandoval, S., & Tobías, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14122703 · Cited by 79
“Additionally, functional groups, hydrophilicity, attachment and conjugation with targeting ligands also comprise the essential parameters that need to be considered [9,10].”
BackgroundImpact of nanotechnology on the delivery of natural products for cancer prevention and therapy
Siddiqui, I. A., & Sanna, V. (2016) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600035 · Cited by 76
Novel amphiphilic chitosan nanocarriers for sustained oral delivery of hydrophobic drugs
Motiei, M., & Kashanian, S. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.12.035 · Cited by 74
Engineered Porphyrin Loaded Core-Shell Nanoparticles for Selective Sonodynamic Anticancer Treatment
Varchi, G., Foglietta, F., Canaparo, R., Ballestri, M., Arena, F., Sotgiu, G., Guerrini, A., Nanni, C., Cicoria, G., Cravotto, G., et al. (2015) · Nanomedicine · doi:10.2217/nnm.15.150 · Cited by 70
Role of membrane-embedded drug efflux ABC transporters in the cancer chemotherapy
Gupta, S. K., Singh, P., Ali, V., & Verma, M. (2020) · Oncology Reviews · doi:10.4081/oncol.2020.448 · Cited by 79
Recent advances in co-delivery nanosystems for synergistic action in cancer treatment
de Carvalho, B. G., Vit, F. F., Carvalho, H. F., Han, S. W., & de la Torre, L. G. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb02168g · Cited by 78
Smart Nanotherapeutics and Lung Cancer
Doroudian, M., Azhdari, M. H., Goodarzi, N., O’Sullivan, D., & Donnelly, S. C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111972 · Cited by 75
“This process is based on nanoparticle physiochemical properties and intrinsic tumor features and leads to drug accumulation at the tumor site [25,29].”
BackgroundJeong, J. Y., Hong, E., Lee, S. Y., Lee, J., Song, J.-H., Ko, S.-H., Shim, J.-S., Choe, S., Kim, D., Ko, H., et al. (2017) · Acta Biomaterialia · doi:10.1016/j.actbio.2017.02.030 · Cited by 72
Meshkini, A., & Oveisi, H. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.07.006 · Cited by 79
Island Growth in the Seed-Mediated Overgrowth of Monometallic Colloidal Nanostructures
Wang, G., Liu, Y., Gao, C., Guo, L., Chi, M., Ijiro, K., Maeda, M., & Yin, Y. (2017) · Chem · doi:10.1016/j.chempr.2017.08.004 · Cited by 74
Drug self-assembly for synthesis of highly-loaded antimicrobial drug-silica particles
Stewart, C. A., Finer, Y., & Hatton, B. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-19166-8 · Cited by 84
Kwak, H. W., Lee, H., Lee, M. E., & Jin, H. (2018) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2018.07.289 · Cited by 71
Emerging nanomedicines for anti-stromal therapy against desmoplastic tumors
Han, X., Xu, Y., Geranpayehvaghei, M., Anderson, G. J., Li, Y., & Nie, G. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2019.119745 · Cited by 71
Liu, J., Wang, Y., Liu, X., Duan, L.-Y., Tang, H., Yu, R., & Jiang, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01667 · Cited by 71
Zhang, Y. S., & Khademhosseini, A. (2015) · Nanomedicine · doi:10.2217/nnm.15.18 · Cited by 75
Self-citationAntibody-Targeted Nanoparticles for Cancer Treatment
Carter, T. J., Mulholland, P. J., & Chester, K. A. (2016) · Immunotherapy · doi:10.2217/imt.16.11 · Cited by 78
“A number of untargeted NPs have entered in early phase clinical cancer trials [26].”
BackgroundMethodXu, R., Chi, W., Zhao, Y., Tang, Y., Jing, X., Wang, Z., Zhou, Y., Shen, Q., Zhang, J., Yang, Z., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c04465 · Cited by 70
Jiang, X., Lee, M. J., Xia, J., Luo, T., Liu, J., Rodriguez, M., & Lin, W. (2022) · ACS Nano · doi:10.1021/acsnano.2c09788 · Cited by 70
Kang, T., Zhu, Q., Jiang, D., Feng, X., Feng, J., Jiang, T., Yao, J., Jing, Y., Song, Q., Jiang, X., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.05.037 · Cited by 70
“[3] Sun T, Zhang YS, Pang B, Hyun DC, Yang M, Xia Y .”
BackgroundMahdavi, M., Fattahi, A., Tajkhorshid, E., & Nouranian, S. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00956 · Cited by 71
TRAIL in oncology: From recombinant TRAIL to nano- and self-targeted TRAIL-based therapies
Dianat‐Moghadam, H., Heidarifard, M., Mahari, A., Shahgolzari, M., Keshavarz, M., Nouri, M., & Amoozgar, Z. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104716 · Cited by 70
Yang, Z., Zhang, N., Ma, T., Liu, L., Zhao, L., & Xie, H. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1797243 · Cited by 71
“…used to develop nano-scale formulations for improving the therapeutic efficacy and reducing the sideeffects, especially the stimuli-responsive biomaterials-based DDSs (Gong et al. 2012; Mura et al. 2013; Yin et al. 2013; Li et al. 2014; Sun et al. 2014; Masood 2016; Qiao et al. 2019).”
BackgroundInfluentialNanoengineered electrospun fibers and their biomedical applications: a review
Zhang, X., Shi, X., Gautrot, J. E., & Peijs, T. (2020) · Nanocomposites · doi:10.1080/20550324.2020.1857121 · Cited by 78
Zeng, C., Shang, W., Wang, K., Chi, C., Jia, X., Fang, C., Yang, D., Ye, J., Fang, C., & Tian, J. (2016) · Scientific Reports · doi:10.1038/srep21959 · Cited by 70
Zhong, T., Yao, X. S., Zhang, S., Guo, Y., Duan, X.-C., Ren, W., Huang, D., Yin, Y.-F., & Zhang, X. (2016) · Scientific Reports · doi:10.1038/srep36614 · Cited by 69
“Preparation by precipitation is an easy procedure which involves (1) dissolving the conjugate in an organic solvent, (2) then mixing the homogeneous solution with water, and (3) after the nanomedicine is self-assembled, the organic solvent can be removed to form a dispersion of spherical nanoparticles in aqueous solut…”
MethodNanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics
Zhang, Y., Zou, Z., Liu, S., Miao, S., & Liu, H. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.954470 · Cited by 86
Self-citationLin, M., Wang, D., Liu, S., Huang, T., Sun, B., Cui, Y., Zhang, D., Sun, H., Zhang, H., Sun, H., et al. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b05866 · Cited by 69
Liu, R., Zhang, H., Zhang, F., Wang, X., Liu, X., & Zhang, Y. (2018) · Materials Science and Engineering C · doi:10.1016/j.msec.2018.10.093 · Cited by 69
Self-citationLiposomes modified with bio-substances for cancer treatment
Li, Y., Cong, H., Wang, S., Yu, B., & Shen, Y. (2020) · Biomaterials Science · doi:10.1039/d0bm01531h · Cited by 68
Qamar, H., Hussain, K., Soni, A., Khan, A., Hussain, T., & Chénais, B. (2021) · Molecules · doi:10.3390/molecules26010247 · Cited by 75
Yang, J., Wang, X., Wang, B., Park, K., Wooley, K. L., & Zhang, S. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114525 · Cited by 71
“There are another three drugs approved by regulatory agents outside the United States [11,12].”
BackgroundBone-Targeted Mesoporous Silica Nanocarrier Anchored by Zoledronate for Cancer Bone Metastasis
Sun, W., Han, Y., Li, Z., Ge, K., & Zhang, J. (2016) · Langmuir · doi:10.1021/acs.langmuir.6b02228 · Cited by 67
Protease-Sensitive Nanomaterials for Cancer Therapeutics and Imaging
Anderson, C. F., & Cui, H. (2017) · Industrial & Engineering Chemistry Research · doi:10.1021/acs.iecr.7b00990 · Cited by 71
Dang, H. P., Shabab, T., Shafiee, A., Peiffer, Q. C., Fox, K. E., Tran, N. L., Dargaville, T. R., Hutmacher, D. W., & Tran, P. A. (2019) · Biofabrication · doi:10.1088/1758-5090/ab14ff · Cited by 75
Mohapatra, S., Rout, S. R., Das, R. K., Nayak, S., & Ghosh, S. K. (2016) · Langmuir · doi:10.1021/acs.langmuir.5b03898 · Cited by 67
Montha, W., Maneeprakorn, W., Buatong, N., Tang, I., & Pon‐On, W. (2015) · Materials Science and Engineering C · doi:10.1016/j.msec.2015.09.098 · Cited by 66
Guan, T., Shang, W., Li, H., Yang, X., Fang, C., Tian, J., & Wang, K. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00065 · Cited by 67
High Throughput Nanoliposome Formation Using 3D Printed Microfluidic Flow Focusing Chips
Chen, Z., Han, J. Y., Shumate, L., Fedak, R., & DeVoe, D. L. (2019) · Advanced Materials Technologies · doi:10.1002/admt.201800511 · Cited by 66
NanoRNP Overcomes Tumor Heterogeneity in Cancer Treatment
Liu, Q., Cai, J., Zheng, Y., Tan, Y., Wang, Y., Zhang, Z., Zheng, C., Zhao, Y., Liu, C., An, Y., et al. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b02501 · Cited by 68
Taking advantage of cellular uptake of ferritin nanocages for targeted drug delivery
Tesařová, B., Musílek, K., Rex, S., & Heger, Z. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.026 · Cited by 70
Probing the biological obstacles of nanomedicine with gold nanoparticles
Li, B., & Lane, L. A. (2018) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1542 · Cited by 77
“…X-ray computed tomography (Dorsey et al., 2013; Shilo, Reuveni, Motiei, & Popovtzer, 2012), positron emission tomography (Frellsen et al., 2016; Sun et al., 2014b; Wang et al., 2012; Yang et al., 2017; Zhao et al., 2016), and Cerenkov luminescence imaging (Lee et al., 2016; Wang et al., 2013a).”
BackgroundTrofymchuk, K., Valančiūnaitė, J., Andreiuk, B., Reisch, A., Collot, M., & Klymchenko, A. S. (2019) · Journal of Materials Chemistry B · doi:10.1039/c8tb02781a · Cited by 70
Liu, J., Zhang, Y., Zeng, Q., Zeng, H., Liu, X., Wu, P.-H., Xie, H., He, L., Long, Z., Lu, X., et al. (2019) · Science Advances · doi:10.1126/sciadv.aaw6499 · Cited by 65
“Nanoparticles within the 500-nm range should be suitable candidates as carriers to deliver siRNA into cells, according to previous studies (22, 23).”
BackgroundSelf-citationZhang, H.-J., Zhao, X., Chen, L., Yang, C., & Yan, X. (2020) · Talanta · doi:10.1016/j.talanta.2020.121209 · Cited by 66
Li, H., Zhang, Y., Shu, H., Lv, W., Su, C., & Nie, F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121412 · Cited by 75
Self-citationZhu, C., Ma, Q., Gong, L., Di, S., Gong, J., Wang, Y., Xiao, S., Zhang, L., Zhang, Q., Fu, J., et al. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.01.019 · Cited by 66
Recent developments and applications of smart nanoparticles in biomedicine
Campora, S., & Ghersi, G. (2022) · Nanotechnology Reviews · doi:10.1515/ntrev-2022-0148 · Cited by 84
Zhang, G., Chen, X., Chen, X., Du, K., Ding, K., He, D., Ding, D., Hu, R., Qin, A., & Tang, B. Z. (2023) · ACS Nano · doi:10.1021/acsnano.3c03005 · Cited by 70
Tian, J., Yao, C., Yang, W.-L., Zhang, L., Zhang, D., Wang, H., Zhang, F., Liu, Y., & Li, Z. (2017) · Chinese Chemical Letters · doi:10.1016/j.cclet.2017.01.010 · Cited by 67
How cells engulf: a review of theoretical approaches to phagocytosis
Richards, D. M., & Endres, R. G. (2017) · Reports on Progress in Physics · doi:10.1088/1361-6633/aa8730 · Cited by 72
“Micro- and nanoparticle drug carriers are an increasingly promising avenue for combating a range of diseases, including HIV [21], TB [22] and cancer [23, 24].”
BackgroundFabrication of zwitterionic and pH-responsive polyacetal dendrimers for anticancer drug delivery
Wang, Y., Huang, D., Wang, X., Yang, F., Shen, H. Y., & Wu, D. (2019) · Biomaterials Science · doi:10.1039/c9bm00606k · Cited by 64
Baghirov, H., Snipstad, S., Sulheim, E., Berg, S., Hansen, R., Thorsen, F., Mørch, Y. A., Davies, C. D. L., & Åslund, A. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191102 · Cited by 62
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
Huang, D., Zhao, C., Wen, B., Fu, X., Shang, L., Kong, W., & Zhao, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.134871 · Cited by 66
Gopmandal, P. P., & Duval, J. F. L. (2022) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2022.101605 · Cited by 68
Engineered g-C3N4 Quantum Dots for Tunable Two-Photon Imaging and Photodynamic Therapy
Wu, X., Yang, L., Luo, L., Shi, G., Wei, X., & Wang, F. (2019) · ACS Applied Bio Materials · doi:10.1021/acsabm.9b00055 · Cited by 64
Tuguntaev, R. G., Chen, S., Eltahan, A. S., Mozhi, A., Jin, S., Zhang, J., Li, C., Wang, P. C., & Liang, X. (2017) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b03877 · Cited by 63
Zhang, T., Jiang, Z., Xve, T., Sun, S., Li, J., Ren, W., Wu, A., & Huang, P. (2019) · Nanoscale · doi:10.1039/c9nr05671h · Cited by 63
Mitochondrion-targeted selenium nanoparticles enhance reactive oxygen species-mediated cell death
Zhuang, Y., Li, L., Feng, L., Wang, S., Su, H., Liu, H., Liu, H., & Wu, Y. (2020) · Nanoscale · doi:10.1039/c9nr09039h · Cited by 66
Nanocarrier-based Drug Delivery System for Cancer Therapeutics: A Review of the Last Decade
Sohail, M., Guo, W., Li, Z., Xu, H. Z., Zhao, F., Chen, D., & Fu, F. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666201005111722 · Cited by 63
Advances in Functionalized Photosensitive Polymeric Nanocarriers
Fernández, M., & Orozco, J. (2021) · Polymers · doi:10.3390/polym13152464 · Cited by 71
“They are very large glycoproteins (150 kDa) whose principal role is to recognize antigens from the circulation, facilitating the activity of the macrophages, conferring high immunogenicity to the NPs after conjugation [21,57].”
BackgroundEgea-Benavente, D., Ovejero, J. G., Morales, M. P., & Barber, D. F. (2021) · Cancers · doi:10.3390/cancers13184583 · Cited by 69
An update on dual targeting strategy for cancer treatment
Taghipour, Y. D., Zarebkohan, A., Salehi, R., Rahimi, F., Torchilin, V. P., Hamblin, M. R., & Seifalian, A. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.06.044 · Cited by 72
Xing, Y., Yang, J., Peng, A., Qian, Y., Liu, Y., Pan, P., & Liu, Q. (2024) · Advanced Materials · doi:10.1002/adma.202412730 · Cited by 69
SiRNA-mediated in vivo gene knockdown by acid-degradable cationic nanohydrogel particles
Leber, N., Kaps, L., Aslam, M., Schupp, J., Brose, A., Schaeffel, D., Fischer, K., Diken, M., Strand, D. J., Koynov, K., et al. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.006 · Cited by 71
Du, B., Ma, C., Ding, G., Han, X., Li, D., Wang, E., & Wang, J. (2017) · Small · doi:10.1002/smll.201603275 · Cited by 65
Bench-to-bedside translation of dendrimers: Reality or utopia? A concise analysis
Mignani, S. M., Rodrigues, J., Tomás, H., Roy, R., Shi, X., & Majoral, J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.11.007 · Cited by 66
Nanoparticles as Tools to Target Redox Homeostasis in Cancer Cells
Ciccarese, F., Raimondi, V., Sharova, E., Silic‐Benussi, M., & Ciminale, V. (2020) · Antioxidants · doi:10.3390/antiox9030211 · Cited by 69
“Many anticancer drugs have pharmaceutical limitations, including poor solubility, low bioavailability and high cytotoxicity for noncancer cells [48].”
BackgroundNanoparticles guided drug delivery and imaging in gastric cancer
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.006 · Cited by 62
Nagarajan, V., & Chandiramouli, R. (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.11.083 · Cited by 62
Current status and future prospects of nanomedicine for arsenic trioxide delivery to solid tumors
Sönksen, M., Kerl, K., & Bunzen, H. (2021) · Medicinal Research Reviews · doi:10.1002/med.21844 · Cited by 62
“In recent years, the advent of nanoparticles as novel drug delivery systems (DDSs) has offered new possibilities for improved delivery of chemotherapeutic drugs, for example, by increasing their bioavailability, decreasing their effects on healthy tissue, or enhancing their uptake by tumor cells (see Sun et al.46 for…”
Background
Metadata
- Authors
- Sun, T., Zhang, Y. S., Pang, B., Hyun, D. C., Yang, M., & Xia, Y.
- Affiliations
- Georgia Institute of Technology (US)
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-10-07
- Volume
- 53
- Issue
- 46
- Pages
- 12320-12364
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2134726513
- Cited by
- 2,164
- References
- 578
- Citations by year
- 2026: 57 · 2025: 146 · 2024: 163 · 2023: 153 · 2022: 209 · 2021: 200 · 2020: 221 · 2019: 237 · 2018: 257 · 2017: 230 · 2016: 180 · 2015: 109 · 2014: 2
- FWCI
- 11.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Physical Sciences › Materials Science › Polymers and Plastics › Dendrimers and Hyperbranched Polymers
- Keywords
- engineered nanoparticles, drug delivery, cancer therapy, targeted drug delivery, enhanced permeability and retention effect, pH-responsive delivery, tumor-targeting ligands, tissue distribution, circulation half-life, immunogenicity, combination therapy, multidrug resistance, contrast media, theranostics, nanoparticle surface modification
- MeSH terms
- Animals, Antineoplastic Agents, Delayed-Action Preparations, Humans, Neoplasms, Drug Delivery Systems, Nanotechnology, Nanomedicine, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.